GLP-1 based therapies: differential effects on fasting and postprandial glucose

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

(2016) Filip Krag Knop et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

(2011) Anne Flint et al.   ADVANCES IN THERAPY

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

(2011) Robert Ratner et al.   Cardiovascular Diabetology

Neuroprotective properties of GLP-1: theoretical and practical applications

(2011) Jens Juul Holst et al.   CURRENT MEDICAL RESEARCH AND OPINION

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

(2011) Steven P Marso et al.   Diabetes & Vascular Disease Research

Therapy in the Early Stage: Incretins

(2011) S. Cernea et al.   DIABETES CARE

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors

(2011) D. Dicker   DIABETES CARE

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study

(2011) G. E. Umpierrez et al.   DIABETES OBESITY & METABOLISM

A cohort study of acute pancreatitis in relation to exenatide use

(2011) D. D. Dore et al.   DIABETES OBESITY & METABOLISM

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

(2011) K. R. Hjøllund et al.   DIABETOLOGIA

Novel GLP-1 receptor agonists for diabetes

(2011) Alan J Garber   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Lixisenatide for type 2 diabetes mellitus

(2011) Mikkel Christensen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

(2011) Laszlo Hegedüs et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Control of Postprandial Glucose Levels with Insulin in Type 2 Diabetes

(2011) Thomas Blevins   POSTGRADUATE MEDICINE

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

(2010) Michael A. Nauck   AMERICAN JOURNAL OF MEDICINE

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

(2010) Mathijs C. Bunck et al.   ATHEROSCLEROSIS

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

(2010) Mark Fineman et al.   CLINICAL PHARMACOKINETICS

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

(2010) K. J. Hare et al.   DIABETES

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

(2010) D. J. Drucker et al.   DIABETES CARE

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Diabetes and Cancer: A consensus report

(2010) E. Giovannucci et al.   DIABETES CARE

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

(2010) Lotte Bjerre Knudsen et al.   ENDOCRINOLOGY

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy

(2010) Mary Parks et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes

(2010) Walid K.H. Fakhoury et al.   PHARMACOLOGY

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

(2010) Robert Frederich et al.   POSTGRADUATE MEDICINE

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms

(2009) Sandra Bonuccelli et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

(2009) J. A. DAVIDSON   CLEVELAND CLINIC JOURNAL OF MEDICINE

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

(2009) M. A. Bush et al.   DIABETES OBESITY & METABOLISM

Exenatide: a review from pharmacology to clinical practice

(2009) R. Gentilella et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

(2009) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Diabetes and cancer

(2009) Paolo Vigneri et al.   ENDOCRINE-RELATED CANCER

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

The role of gut hormones in the regulation of body weight and energy homeostasis

(2009) Efthimia Karra et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long-Acting, Potent Glucagon-Like Peptide-1 Analog

(2009) Jerry Meece   PHARMACOTHERAPY

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism

(2008) B. Ahrén et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Intestinal Hormones and Regulation of Satiety: The Case for CCK, GLP-1, PYY, and Apo A-IV

(2008) David D'Alessio   JOURNAL OF PARENTERAL AND ENTERAL NUTRITION

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Treatment of type 2 diabetes with incretin-based therapies

(2008) Sten Madsbad   LANCET

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

(2008) Helle Linnebjerg et al.   REGULATORY PEPTIDES